Nov. 9 (UPI) -- Drugmaker Pfizer and partner BioNTech announced Monday that tests of their COVID-19 vaccine has shown the first scientific evidence that it can block the coronavirus disease in about 90% of humans.
The results of the companies' late-stage clinical trial showed that just 10% of almost 100 test subjects who tested positive for COVID-19 had received the vaccine rather than a placebo, according to what the firms said was an interim analysis of its third-stage trial.